(Naxitamab)Biosimilar Reference Antibody-GS40463

货号：GS40463

Naxitamab (brand name Danyelza®) is a humanized monoclonal antibody that targets GD2 (disialoganglioside GD2), a glycolipid antigen highly expressed on neuroblastoma cells and some other solid tumors (e.g., osteosarcoma, melanoma). It is an IgG1 isotype engineered to enhance antibody‑dependent cellular cytotoxicity (ADCC). By binding to GD2, naxitamab directs immune cells (primarily natural killer cells and macrophages) to attack GD2‑positive tumor cells. It is approved in combination with granulocyte‑macrophage colony‑stimulating factor (GM‑CSF) for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high‑risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy.